Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thailand Issues Deadline For Drug Price Slashes Or Compulsory Licenses (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Thailand's chief negotiator in price talks with foreign pharmaceuticals says Novartis and Sanofi-Aventis have until the end of this month to lower the costs for two drugs by more than 60 percent or face compulsory licenses. Dr. Siriwat Tiptaradol, chairman of the negotiating committee for compulsory licensing of patented drugs, said Sanofi-Aventis offered to trim its price by only 10 percent for Taxotere (docetaxel) for treating lung and breast cancer. Roche's OSI Pharms unit was expected to make a proposal for its Tarceva (erlotinib) before the end of December. Siriwat said Sanofi and Novartis, whose Femara (letrozole) is included in the 60 percent demand, have until the end of the month to respond to the demand or he will end negotiations and report to the Public Health minister, who will then consider compulsory licensing. Siriwat said a Novartis proposal to distribute its Gleevec (imatinib mesylate) leukemia drug for free to registered cancer patients was satisfactory. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts